These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 23481323)

  • 1. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
    Currier MA; Eshun FK; Sholl A; Chernoguz A; Crawford K; Divanovic S; Boon L; Goins WF; Frischer JS; Collins MH; Leddon JL; Baird WH; Haseley A; Streby KA; Wang PY; Hendrickson BW; Brekken RA; Kaur B; Hildeman D; Cripe TP
    Mol Ther; 2013 May; 21(5):1014-23. PubMed ID: 23481323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.
    Eshun FK; Currier MA; Gillespie RA; Fitzpatrick JL; Baird WH; Cripe TP
    Gene Ther; 2010 Jul; 17(7):922-9. PubMed ID: 20508601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
    Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
    Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
    Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
    PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
    Yoo JY; Pradarelli J; Haseley A; Wojton J; Kaka A; Bratasz A; Alvarez-Breckenridge CA; Yu JG; Powell K; Mazar AP; Teknos TN; Chiocca EA; Glorioso JC; Old M; Kaur B
    Clin Cancer Res; 2012 Sep; 18(18):4931-41. PubMed ID: 22753591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of the tumor angiogenesis inhibitor bevacizumab and intratumoral oncolytic herpes virus injections as a treatment strategy for human gastric cancers.
    Deguchi T; Shikano T; Kasuya H; Nawa A; Fujiwara S; Takeda S; Gewen T; Sahin TT; Yamada S; Kanzaki A; Yamamura K; Fujii T; Sugimoto H; Nomoto S; Fukuda S; Nishikawa Y; Kodera Y; Nakao A
    Hepatogastroenterology; 2012 Sep; 59(118):1844-50. PubMed ID: 22172413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy.
    Adelfinger M; Gentschev I; Grimm de Guibert J; Weibel S; Langbein-Laugwitz J; Härtl B; Murua Escobar H; Nolte I; Chen NG; Aguilar RJ; Yu YA; Zhang Q; Frentzen A; Szalay AA
    PLoS One; 2014; 9(8):e104337. PubMed ID: 25093734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
    Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
    Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
    Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
    Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
    Yoo JY; Kim JH; Kwon YG; Kim EC; Kim NK; Choi HJ; Yun CO
    Mol Ther; 2007 Feb; 15(2):295-302. PubMed ID: 17235307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.
    Meisen WH; Wohleb ES; Jaime-Ramirez AC; Bolyard C; Yoo JY; Russell L; Hardcastle J; Dubin S; Muili K; Yu J; Caligiuri M; Godbout J; Kaur B
    Clin Cancer Res; 2015 Jul; 21(14):3274-85. PubMed ID: 25829396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma.
    Xu B; Tian L; Chen J; Wang J; Ma R; Dong W; Li A; Zhang J; Antonio Chiocca E; Kaur B; Feng M; Caligiuri MA; Yu J
    Nat Commun; 2021 Oct; 12(1):5908. PubMed ID: 34625564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma.
    Armando F; Fayyad A; Arms S; Barthel Y; Schaudien D; Rohn K; Gambini M; Lombardo MS; Beineke A; Baumgärtner W; Puff C
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent.
    Totsch SK; Ishizuka AS; Kang KD; Gary SE; Rocco A; Fan AE; Zhou L; Valdes PA; Lee S; Li J; Peruzzotti-Jametti L; Blitz S; Garliss CM; Johnston JM; Markert JM; Lynn GM; Bernstock JD; Friedman GK
    Mol Cancer Ther; 2024 Sep; 23(9):1273-1281. PubMed ID: 38710101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
    Wang Y; Zhou X; Wu Z; Hu H; Jin J; Hu Y; Dong Y; Zou J; Mao Z; Shi X; Huo Y; Lyu J; Fang Z; Zhang W; Zhu Y; Li B; Liu B
    Hum Gene Ther; 2019 May; 30(5):651-660. PubMed ID: 30499341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy.
    Frentzen A; Yu YA; Chen N; Zhang Q; Weibel S; Raab V; Szalay AA
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12915-20. PubMed ID: 19617539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.